Product
TTX-080
1 clinical trial
1 indication
Indication
CancerClinical trial
A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination With Pembrolizumab or Cetuximab in Patients With Advanced Solid Refractory/Resistant MalignanciesStatus: Active (not recruiting), Estimated PCD: 2023-12-31